Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The ESMO World Congress on Gastrointestinal Cancer represents the year’s premier gathering of international oncology professionals who are dedicated to improving the lives of patients impacted by malignancies of the GI tract.

ESMO WCGIC 2022

ESMO World Congress On Gastrointestinal Cancer 2022
29 Jun–02 July 2022 | Barcelona, Spain, and Online

ESMO WCGIC 2022

ESMO World Congress On Gastrointestinal Cancer 2022
29 Jun–02 July 2022 | Barcelona, Spain, and Online
The ESMO World Congress on Gastrointestinal Cancer represents the year’s premier gathering of international oncology professionals who are dedicated to improving the lives of patients impacted by malignancies of the GI tract.
CRICKET and CAVE: cetuximab for the treatment of mCRC 1:35
CRICKET and CAVE: cetuximab for the treatment of mCRC
Erika Martinelli • 14 Jul 2022
Pooled analysis from the CRICKET and CAVE trials for the treatment of mCRC 1:53
Pooled analysis from the CRICKET and CAVE trials for the treatment of mCRC
Erika Martinelli • 14 Jul 2022
Updates on biomarkers of resistance to CRC treatment 1:47
Updates on biomarkers of resistance to CRC treatment
Erika Martinelli • 14 Jul 2022
Updates in colorectal cancer research from ESMO WCGIC 2022 2:06
Updates in colorectal cancer research from ESMO WCGIC 2022
Erika Martinelli • 14 Jul 2022
Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinoma 3:30
Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinoma
Arndt Vogel • 22 Jul 2022
Targeted therapies for cholangiocarcinoma 2:26
Targeted therapies for cholangiocarcinoma
Arndt Vogel • 22 Jul 2022
HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC? 3:34
HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC?
Arndt Vogel • 22 Jul 2022
KEYNOTE-224: Second-line pembrolizumab for advanced hepatocellular carcinoma 2:25
KEYNOTE-224: Second-line pembrolizumab for advanced hepatocellular carcinoma
Arndt Vogel • 22 Jul 2022
CheckMate 648: Novel treatment for patients with advanced esophageal squamous cell carcinoma 3:05
CheckMate 648: Novel treatment for patients with advanced esophageal squamous cell carcinoma
Hisato Kawakami • 5 Jul 2022
Subgroup analysis of the TOPAZ-1 study by primary tumor location 5:45
Subgroup analysis of the TOPAZ-1 study by primary tumor location
Aiwu Ruth He • 5 Jul 2022
Highlights in colorectal cancer from ESMO WCGIC 2022 1:49
Highlights in colorectal cancer from ESMO WCGIC 2022
Heinz-Josef Lenz • 13 Jul 2022
Future developments in immunotherapy for treatment of biliary tract cancer 2:05
Future developments in immunotherapy for treatment of biliary tract cancer
Aiwu Ruth He • 5 Jul 2022
Highlights in biliary tract and liver cancers from ESMO WCGIC 2022 1:11
Highlights in biliary tract and liver cancers from ESMO WCGIC 2022
Aiwu Ruth He • 5 Jul 2022
Metastatic seeding in clinically undetectable primary CRC 1:34
Metastatic seeding in clinically undetectable primary CRC
Heinz-Josef Lenz • 13 Jul 2022
Identification and targeting of rare genomic alterations in metastatic CRC 2:04
Identification and targeting of rare genomic alterations in metastatic CRC
Heinz-Josef Lenz • 13 Jul 2022
TAS-102 plus bevacizumab vs. TAS-102 alone for previously treated metastatic esophagogastric cancer 3:54
TAS-102 plus bevacizumab vs. TAS-102 alone for previously treated metastatic esophagogastric cancer
Per Pfeiffer • 27 Jun 2022
The content of VJOncology is intended for healthcare professionals